1 / 32

Targeting Glioblastoma: EGFR and Novel Approaches to Therapy

Targeting Glioblastoma: EGFR and Novel Approaches to Therapy. Glioblastoma: The Current State of Affairs. No Improvement With Temozolomide Dose Intensification or Treatment Prolongation. Treatment at Recurrence. Glioblastoma: Improving Outcomes.

Jims
Download Presentation

Targeting Glioblastoma: EGFR and Novel Approaches to Therapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Targeting Glioblastoma: EGFR and Novel Approaches to Therapy

  2. Glioblastoma: The Current State of Affairs

  3. No Improvement With Temozolomide Dose Intensification or Treatment Prolongation

  4. Treatment at Recurrence

  5. Glioblastoma: Improving Outcomes

  6. No Survival Benefit of Adding Bevacizumab to Standard of Care, Despite Improved PFS

  7. Immunotherapy: No Established Improvement of Outcome in Glioblastoma

  8. Promise of Personalized Treatment Strategies Has Not Yet Delivered for Glioblastoma and Other Gliomas

  9. EGFR and Glioblastoma: Still a Relevant Target?

  10. Trials of EGFR Inhibition in Recurrent Glioblastoma Invariably Failed

  11. Why Did We Fail, Despite the Prominent Role of EGFR Signalling in Glioblastoma?

  12. BRAF Mutations in Glioma: An Actionable Target

  13. Ongoing Inhibitor Studies With EGFR Inhibitors

  14. Nanocell, EGFR, and Doxorubicin: EnGeneIC Delivery Vehicle (EDV)

  15. Current Approaches to Targeted Therapies: Ligand‑Compound Constructs

  16. Antibody-Drug Conjugates: A Novel and Clinically Successful Approach

  17. Antibody-Drug Conjugates: Proof of Concept and MOA

  18. Depatux-M (ABT-414): ADC of ABT-806 With MMAF Attached

  19. Phase 1 M12-356: Depatux-M in EGFR-Amplified GBM

  20. Depatux-M: Toxicity Profile

  21. Depatux-M: Toxicity Profile: Response and Duration of Study in Phase 1 Expansion Cohorts on EGFR-Amplified Recurrent GBM

  22. Depatux-M: Clinical Development Program:INTELLANCE1 and INTELLANCE2 Pivotal Studies

  23. INTELLANCE 2 Phase 2 Trial DesignM14-483/EORTC-1410-BTG

  24. Long-Term Follow-Up: Treatment and Time Since TMZ

  25. Long-Term Follow-Up: Treatment and Methylation Status

  26. Depatux-M: Current Status

  27. Rindopepimut: EGFRvIII Vaccination

  28. Adoptive T-Cell Therapy With CAR-Redirected T Lymphocytes

  29. CAR-T Cells: A Treatment Alternative in Glioma?

  30. Conclusion: Ongoing Approaches Targeting EGFR

  31. Abbreviations

  32. Abbreviations (cont)

More Related